Mounjaro is one of the most effective weight loss medications ever studied. In the landmark SURMOUNT-1 trial, participants on the highest dose lost an average of 20.9% of their body weight over 72 weeks, which translates to roughly 50 pounds for someone starting at 230. Even the lowest dose produced a 15% reduction, a result that surpasses what most other medications on the market deliver.
The drug’s active ingredient, tirzepatide, is also sold under the brand name Zepbound when prescribed specifically for weight management. Mounjaro is the same molecule but is FDA-approved for type 2 diabetes. Regardless of brand name, the weight loss results are identical.
How Much Weight People Actually Lose
The SURMOUNT-1 trial tested three doses of tirzepatide against a placebo in people with obesity who did not have diabetes. All participants also followed a reduced-calorie diet and increased physical activity. At 72 weeks, the average body weight reduction by dose was:
- 5 mg: 15% of starting body weight
- 10 mg: 19.5%
- 15 mg: 20.9%
For context, the placebo group lost about 3%. These are averages, so some people lost considerably more and others less. But the consistency across doses is notable: even the starting maintenance dose of 5 mg produced clinically meaningful results that exceed what older weight loss drugs typically achieve.
When You Can Expect to See Results
Weight loss with Mounjaro begins quickly relative to many other treatments. In clinical trials, participants lost just under 4% of their starting body weight after four weeks. By six weeks, that number climbed to 5-6%, and by eight weeks it reached roughly 6-7%. At the four-month mark, average weight loss was about 11%.
The trajectory matters here. Most of the weight comes off during the first 40 to 52 weeks, with the curve gradually flattening as you approach the 72-week mark. The early weeks can feel slow because you start on a low 2.5 mg dose that’s designed purely to let your body adjust, not to produce full weight loss effects. After four weeks at that introductory dose, you move up to 5 mg, and from there your doctor can increase by 2.5 mg increments every four weeks until you reach a maintenance dose of 5, 10, or 15 mg.
How It Compares to Semaglutide
The most common comparison is with semaglutide, the active ingredient in Ozempic and Wegovy. A systematic review and meta-analysis that pooled data from head-to-head studies found that tirzepatide produced significantly greater weight loss: an additional 4.6 percentage points of body weight reduction and about 4.76 kg (roughly 10.5 pounds) more absolute loss compared to semaglutide.
The gap widens at higher weight loss thresholds. People on tirzepatide were more than twice as likely to lose 10% or more of their body weight, and more than twice as likely to reach the 20% mark. This advantage appears to come from how the drug works at a molecular level.
Why It Works Differently Than Other Medications
Most GLP-1 medications, including semaglutide, target a single hormone receptor involved in appetite and blood sugar regulation. Tirzepatide activates two: the GLP-1 receptor and the GIP receptor. This dual action is what sets it apart.
The GIP receptor is expressed in fat tissue and in areas of the brain that control appetite and metabolism. Research published in PNAS found that an intact GIP system in the brain is necessary to achieve the full appetite-suppressing effect of dual-receptor treatment. In other words, the GIP component isn’t just along for the ride; it’s doing meaningful work.
There’s another molecular quirk that may matter. When tirzepatide activates the GLP-1 receptor, it does so in an unusual way that causes less receptor “burnout” over time compared to how the body’s natural GLP-1 hormone works. This could help explain why the drug maintains strong effects over many months of use, though researchers are still working out the full implications.
Health Benefits Beyond the Scale
Weight loss of this magnitude brings measurable improvements in several health markers. Across the SURPASS clinical trials (which studied tirzepatide in people with type 2 diabetes), participants saw blood sugar levels drop substantially, with hemoglobin A1C reductions between 1.9 and 2.6 percentage points depending on dose.
Blood pressure also improved. Systolic blood pressure fell by 2.8 to 12.6 mmHg across the trials, with the largest drops seen in people who started with the highest readings (above 140 mmHg). Interestingly, weight loss only partially explains these blood pressure improvements. In one trial involving patients with established heart disease, 33-57% of the blood pressure reduction came from effects independent of weight loss, suggesting the drug may have direct cardiovascular benefits. People whose blood pressure was already normal did not experience further drops, which reduces concerns about blood pressure falling too low.
Common Side Effects
The most frequent side effects are gastrointestinal. In clinical trials, nausea affected up to 18% of patients, diarrhea up to 17%, and vomiting up to 9%. These symptoms are most common during the first few weeks and during dose increases, which is why the titration schedule starts low and moves up gradually.
For most people, these side effects are mild to moderate and improve as the body adjusts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help. Some people find that a particular dose works well for weight loss without significant nausea, and they stay there rather than escalating further.
What Happens When You Stop
This is where the picture gets less rosy. The SURMOUNT-4 trial followed people who had lost weight on tirzepatide for a year, then switched half of them to a placebo. Among those who stopped the medication, 82% regained more than a quarter of the weight they had lost within one year. This pattern is consistent with what’s seen with other weight loss medications: the drug manages a chronic condition rather than curing it, and stopping treatment typically leads to regain.
This doesn’t mean the medication “didn’t work.” It means obesity involves persistent biological changes in appetite regulation and metabolism that reassert themselves when the drug is removed. For many people, long-term use is the expectation, similar to how blood pressure medication is taken indefinitely.
Who Qualifies for a Prescription
The FDA approved Zepbound (the weight management version) for adults with a BMI of 30 or higher, or a BMI of 27 or higher if they also have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The medication is meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment.
If you have type 2 diabetes, your doctor may prescribe Mounjaro (the diabetes-approved brand) instead, which can produce the same weight loss while also managing blood sugar. The choice between brand names often comes down to your primary diagnosis and what your insurance covers.